EMEA-000329-PIP02-09-M05

Key facts

Invented name
Aranesp
Active substance
darbepoetin alfa
Therapeutic area
Oncology
Decision number
P/0147/2016
PIP number
EMEA-000329-PIP02-09-M05
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of anaemia due to chronic disorders
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Amgen Europe B.V
United Kingdom
Tel. +44 (0)1223 420305
E-mail: medinfointernational@amgen.com
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-000329-PIP02-09-M05
Compliance opinion date
24/03/2017
Compliance outcome
negative

Decision

How useful was this page?

Add your rating